Companies: 10,795·Total market cap: $144.5T

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.

FHTXNASDAQHealthcare● Active

$3.71

$-0.02(-0.54%)

Market Cap$217828569

P/E Ratio—

52W High$6.95

52W Low$3.27

Avg Volume161K

Open$3.67

Beta2.89

Net Income Financials Revenue

Foghorn Therapeutics Inc. (FHTX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

FHTX · net income · updated Jun 9, 2026

Core profitability metrics

FHTX · net income · margin · TTM · CAGR

Net income was −$74.3M for FY2025 (fiscal year ending 2025-12-31), up 14.2% year-over-year. Net profit margin was -240.3%.

FY2025 Net Income−$74.3M▲ +14.2% YoY

Trailing 12M (TTM)−$75.3Mtrailing 4 quarters sum

Net Profit Margin-240.3%−$74.3M ÷ $30.9M

YoY Change+14.2%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · FHTX net income history · FHTX profit margin

Annual net income data

FHTX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$74.3M▲ +14.2%-240.3%$30.9M

FY2024Loss−$86.6M▲ +12.0%-383.2%$22.6M

FY2023Loss−$98.4M▲ +9.6%-288.2%$34.2M

FY2022Loss−$108.9M▼ 7.5%-566.3%$19.2M

FY2021Loss−$101.3M▼ 47.3%-7681.6%$1.3M

Net income vs peers (Healthcare)

FHTX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Foghorn Therapeutics Inc.YOU

FHTX

−$74.3M+14.2%-240.3%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Foghorn Therapeutics Inc. (FHTX) reported net income of −$74.3M for FY2025 (fiscal year ending 2025-12-31), up 14.2% year-over-year. The net profit margin was -240.3% — meaning the company kept $-2.40 of every dollar of revenue as profit.

Foghorn Therapeutics Inc. has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.

Foghorn Therapeutics Inc.'s net profit margin was -240.3% for FY2025, based on the latest annual results.

Investors sometimes search for "Foghorn Therapeutics Inc. net worth" — the company's market capitalization is a separate figure from FHTX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

FHTX net income · 4 questions

Foghorn Therapeutics Inc. is not currently profitable on an annual basis. The company reported a net loss of $74.3M for FY2025.

is FHTX profitabledoes FHTX make a profitFHTX profitabilityFHTX profitable company

▸ Source: FMP /income-statement · GAAP · Foghorn Therapeutics Inc. · Foghorn Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026